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1 Introduction 
Following the widespread use of combined antiretroviral treatment (cART), the landscape of 
the mortality and morbidity of individuals living with HIV has undergone remarkable changes. 
The proportion of AIDS-defining events and bacterial infections have declined, while non-
AIDS defining events have become more frequent. Although the life expectancy of an HIV-
infected person has improved dramatically and is nearly equivalent to the uninfected 
population, a significant decrease in health-related quality of life has been observed, even in 
virologically stable individuals. Individuals living with HIV have an increased risk of these 
age-related morbidities compared with HIV-negative matched controls. Whether this increased 
risk is caused by differences in lifestyle, such as smoking, alcohol or drug consumption, viral 
replication or immunologic changes or long-term cART toxicities, remains unclear.  
A possible, but non-mutually exclusive explanation for the increased risk for these conditions 
is a chronic HIV-induced inflammatory state. Together with CD4 Th-cell depletion, the mixed 
effects of immune depletion and activation result in immune dysfunction, which is thought to 
be responsible for a chronic inflammatory state with various organ involvement that is often 
considered to be age-related or metabolic. The idea that chronic, ongoing inflammation is 
known to play an important role in several long-term pathologic conditions, including 
carcinogenesis, and has a long history; it was originally described by Virchow in 1863. To date, 
the importance of the inflammatory state has not only been identified in other types of 
malignancies, such as gastric MALT lymphoma or diffuse large B-cell lymphoma arising from 
polyclonal B-cell activation in HCV-infected patients  but also in the pathogenesis of 
atherosclerosis and other age-related and metabolic conditions. Therefore, the initiation of early 
treatment seems to be appropriate for preventing viral replication and the consequent 
inflammatory state.  However, ART-related toxicity and unfavorable metabolic changes remain 
concerning.   
The debate about the importance of ART-related toxicities versus ongoing viral replication, 
chronic inflammation and associated non-AIDS-defining morbidities seems to have ended. The 
recently published and early terminated INSIGHT START study has provided the most 
important evidence supporting the idea that control of viral replication, regardless of CD4 
counts, is beneficial for patients, outweighing the risks of cART toxicities. However, concerns 
regarding complications from long-term ART toxicities, especially in the case of older ART, 
have not been completely resolved. In low and middle income countries, in which the newest 
antiretroviral combinations are not always available or affordable, older drugs with less 
favorable toxicity profiles also contribute to the armamentarium against HIV. In Hungary, a 
significant proportion of patients receive zidovudine and lamivudine containing combinations, 
or they have a history of treatment with older NRTIs or protease inhibitors (PIs). Therefore, 
although no published data are available, there is likely a high proportion of patients with 
metabolic complications. In general, little is known about comorbidities of the Hungarian HIV-
infected population. To date, only a few studies were published, focusing mainly on infectious 
complications 
 
2 
 
In our study, we intended to shed light on hepatic conditions among non-AIDS-defining 
morbidities in the Hungarian HIV-infected population. Liver disease has become one of the 
most important causes of morbidity and mortality in individuals living with HIV, and liver-
related deaths occur ten times more frequently in these individuals than in the general 
population. While hepatitis B or C co-infections remain the most significant cause of liver 
damage, liver-related mortality also affects those infected only with HIV. Long-term 
antiretroviral and non-antiretroviral medications, HIV-induced long-term inflammation, 
metabolic complications and direct cytopathic effects may also contribute to liver damage and 
hepatotoxicity. In addition to fibrosis, there has been increasing concern about the role of non-
alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).  
Currently, the gold standard for the diagnosis and assessment of HS is liver biopsy (LB). 
Limiting factors of LB are cost and rare, but severe, complications, with the additional concerns 
of sampling error and difficulties related to reproducibility. Furthermore, LB allows only 
semiquantitative grading. Given the high proportion of individuals with NAFLD in the general 
population, an invasive method, such as liver stiffness (LS), with possible life-threatening 
complications is impractical for diagnosis. Therefore, increasing attention has been paid to 
numerous non-invasive methods. A recently developed tool is the controlled attenuation 
parameter (CAP), which has demonstrated accurate and reliable measurement of HS and has 
been successfully validated in different patient groups.  
The evaluation and grading of liver fibrosis is facing similar problems to those observed with 
HS. Cross-sectional studies in HIV-mono-infected patients have reported high rates (8.3-
41.9%) of significant liver fibrosis, suggesting that HIV itself may contribute independently to 
liver damage. To date, only limited data are available on the prevalence and risk factors for 
liver fibrosis among HIV-mono-infected patients. Viral replication, low CD4 cell counts and 
long-term exposure to antiretroviral regimes have been identified as risk factors for the 
development of significant liver fibrosis. Like hepatic steatosis, ongoing liver fibrosis is not 
always accompanied by elevated liver enzymes and a diagnosis of liver fibrosis. The prevention 
of progression to liver cirrhosis is an important challenge. As a result, adequate monitoring 
strategies for liver disease are needed to optimize the care of HIV-infected individuals. 
Noninvasive fibrosis determinations, such as liver stiffness measurements (LSM) with transient 
elastography, the aspartate aminotransferase (AST)-to-platelet ratio index (APRI) and the FIB-
4 score, have facilitated cross-sectional and prospective studies to evaluate the prevalence and 
incidence of liver fibrosis in HIV-infected individuals. Liver stiffness, which is a value that 
describes the grade of liver fibrosis, is also simultaneously determined by the CAP 
measurement using transient elastography. Therefore, LSM seems to be a practical method for 
evaluating liver diseases, especially in individuals living with HIV. To date, only a few studies 
using LSM have examined the prevalence and potential risk factors for hepatic fibrosis among 
HIV-mono-infected patients. The use of different cutoff values has resulted in a wide range of 
prevalence estimates. 
While the main pathogenic factors resulting in the development of NAFLD are similar to the 
ones involved in the development of non-AIDS-defining morbidities in HIV-infected patients, 
an increased prevalence in the HIV-infected population is expected. ART may also contribute 
to hepatotoxicity. It should be emphasized that patients with normal liver enzymes can still have 
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significant steatosis and fibrosis. Thus, early detection of HS in HIV-infected patients is the 
cornerstone of prevention of the silent progression of NAFLD to NASH and cirrhosis.  
Surprisingly, data from the HIV-mono-infected population are relatively scarce and are limited 
almost exclusively to hepatitis-co-infected subpopulations. Therefore, data from an unselected 
group of individuals living with HIV, including HIV-mono-infected patients, are urgently 
needed to develop better caring and treatment strategies for PLWH with NAFLD. To achieve 
this goal, the problem of selection and switching of ART in this population should be addressed. 
As a first step, epidemiologic, cross-sectional studies are needed to better characterize the 
prevalence and disease burden. Therefore, we designed and performed a cross-sectional study 
in an unselected group of individuals living with HIV to assess the prevalence of NAFLD and 
to identify associated factors. The aim of our study was to assess the prevalence and severity of 
HS using a continuous CAP value in PLWH and to determine the association with different 
demographic, immunologic and metabolic factors. Given that the data for liver fibrosis in the 
HIV-mono-infected population are also limited, we planned to perform a predefined subgroup 
analysis in this patient population. In contrast to the few published similar studies, we planned 
to use a continuous scale of LS and CAP values as regression endpoints to avoid the information 
loss and uncertainty that arises from cutoff values adopted from other patient populations.   
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2 Study objectives 
 
2.1 Primary objectives 
 To identify a proportion of significant hepatic steatosis in individuals living with HIV 
 To determine the associations between antiretroviral agents and hepatic steatosis in 
individuals living with HIV 
 To determine the associations between HIV-related immunologic parameters and 
hepatic steatosis in individuals living with HIV 
 To determine the associations between metabolic parameters and hepatic steatosis in 
individuals living with HIV 
 
2.2. Secondary objectives 
 To characterize the metabolic profile of the Hungarian HIV-infected population 
 To identify a proportion of significant hepatic fibrosis HIV-mono-infected individuals 
 
2.3. Exploratory objectives 
 To determine the associations between antiretroviral agents and hepatic fibrosis in HIV-
mono-infected individuals without significant alcohol consumption 
 To determine the associations between HIV-related parameters and hepatic fibrosis in 
HIV-mono-infected individuals without significant alcohol consumption 
 To determine the associations between metabolic parameters and hepatic fibrosis in 
HIV-mono-infected individuals without significant alcohol consumption  
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3 Methods 
3.1 Study population 
The investigation was approved by the Institutional Ethics Committee. From March 1, 2014 to 
October 30, 2014, all HIV-infected patients who attended the outpatient clinic at the HIV 
Center, St. Laszlo Hospital, Budapest, Hungary were invited to participate in the study. After 
providing written informed consent, individuals older than 18 years of age were enrolled in the 
study. Pregnant women and patients with unreliable transient elastography measurements were 
excluded. Taking these criteria into account, the final study population consisted of 136 
individuals (Figure 1). A subgroup analysis of HIV-mono-infected individuals without 
documented or suspected significant alcohol consumption (defined by >50 g alcohol daily) was 
also performed.  
3.2 Interview and clinical parameters 
Interviews with the participants were conducted at the Hepatology Center of Buda, Budapest, 
Hungary, on the same day as the transient elastography. Information regarding the medical 
history was collected, including comorbidities, concomitant medications, mode of HIV 
transmission, known length of HIV positivity, history of antiretroviral therapy, alcohol and 
illicit drug intake and smoking habits. Anthropometric and demographic parameters, and 
assessment of facial lipodystrophy, were gathered by an investigator experienced in HIV 
medicine. Information obtained during the interviews regarding comorbidities, concomitant 
medications, biochemical and immunological parameters and history of antiretrovirals was also 
checked retrospectively in the patients’ archived documentation. 
3.3 Transient elastography 
Vibration controlled transient elastography (VTCE) is a non-invasive method to quantify liver 
fibrosis. This technique uses both ultrasound (5 MHz) and low-frequency (50 Hz) elastic shear 
waves, with a propagation velocity that is related to tissue elasticity. VTCE is approved by the 
FDA and is recommended by different international and national guidelines e.g., Hungarian 
consensus guidelines for viral hepatitis. 
CAP measurements based on VTCE were also simultaneously performed. CAP is the name of 
the algorithm that assesses the ultrasonic attenuation coefficient based on the ultrasonic 
properties of the radiofrequency back-propagated signals, or more precisely, it is an estimate of 
the total ultrasonic attenuation at 3.5 MHz. Technical details and validation with histological 
findings have also been extensively described. A cutoff of 238 dB/m was selected to define the 
presence of hepatic steatosis (S1), and cutoff values for more advanced steatosis of 260 dB/m 
(S2) and 292 dB/m (S3) have been applied. Because these cutoffs were adopted from a non-
HIV-infected population, they cannot be reliably transferred to an HIV-infected population. 
Therefore, despite the defined cutoff values, for the univariate and multivariate analyses, a 
continuous scale of CAP values was used. A similar problem was encountered for the liver 
stiffness cutoffs. To overcome this limitation, we used a continuous scale of LS values to 
interpret this variable in the uni- and multivariate analyses. VTCE were performed by an 
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experienced and qualified investigator at the Hepatology Center of Buda, Budapest, Hungary, 
using FibroScan 502 equipment (Fibroscan, EchoSens™, Paris, France).  
 
  
Figure 1. Recruitment Flow of the Study Participants. 
3.4 Statistical analysis 
The primary outcome variable was the CAP value. The univariate association of CAP with 
categorical variables was assessed using a two-independent-sample Mann-Whitney U test. The 
univariate correlation of CAP with continuous variables was assessed using the Pearson (linear) 
and Kendall-τ rank-correlation coefficient. Visualization was performed with scattergrams, 
which indicated the best fitting linear curve and LOWESS-smoother for non-parametric 
regression. Bonferroni correction was performed to counteract problems related to multiple 
comparisons. For the multivariate analysis, prespecified covariates were added to a linear 
regression model, with the CAP value as the response variable, as described by Sulyok et al. 
No interaction was added to the models. Categorical variables were added with Male/No as the 
reference category. The necessity of non-linearity was investigated by extending the model 
using restricted cubic splines and the Wald-F test to assess joint significance. Hurvich and 
Tsai’s corrected Aikake Information Criterion was used to determine the necessity of model 
penalization. The obtained model was checked and passed routine residual diagnostics. To 
internally validate the model, a calibration curve and optimism-corrected R2 were calculated 
using the bootstrap method with 1000 replications. A prespecified, but unpublished, subgroup 
analysis in HIV-mono-infected individuals without significant alcohol intake was also 
performed as described above using liver stiffness as the response variable. Calculations were 
performed using R software version 3.1.2 with a custom script that is available upon request.  
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4 Results 
4.1 Study population characteristics 
Significant steatosis was observed in 65 (47.8%) patients. Twenty-five (18.38%) patients had 
stage 1, 16 (11.75%) stage 2 and 24 (17.65%) stage 3. The median liver stiffness was 5.2 kPa 
(IQR 2). Fifty-two (36.76%) patients had a BMI greater than 25 kg/m2, and obesity (defined by 
a BMI greater than 30 kg/m2) was identified in 6 (4.55%) individuals. Hypertriglyceridemia 
(serum triglyceride levels >1.7 mmol/L) was detected in 57 (41.92%) patients, and 
hypercholesterolemia (serum cholesterol levels >5.2 mmol/L) or low serum HDL-C levels (<1 
mmol/L in men, < 1.3 in women) were observed in 67 (47.8%) individuals. The mode of HIV 
transmission was reported to be sexual intercourse in 134 (98.5%) patients and transfusional or 
coagulation factor product in 2 (1.5%) individuals with hemophilia. Intravenous drug use was 
not reported by any patients. The study population characteristics are summarized in Table 1. 
Anti-HCV antibodies were detected in 13 (9.56%) individuals. Eight patients had S0 stage HS, 
2 had S1 and 3 had S3. The median CAP value was 237 dB/m and 216 dB/m in individuals 
without anti-HCV antibodies (p=0.32). HBsAg was observed in 11 (8.1%) study participants. 
The median CAP did not differ significantly (p=0.632) between patients with (237 dB/m) and 
without (238 dB/m) HBsAg positivity. Four (2.94%) individuals reported more than 50 g of 
daily alcohol intake (median CAP 237 dB/m and 238 dB/m; p=0.515).  
In the subgroup of HIV-mono-infected patients without significant alcohol consumption 
(n=101), LS ranged from 3.0 kPa to 34.3 kPa, with a median value of 5.1 kPa (IQR 1.7). 
According to the HIV/HCV co-infection LS cutoffs, significant liver fibrosis, defined as LS 
<7.2 kPa, was detectable in 10/101 individuals. The presence of cirrhosis (LS >14.6 kPa) was 
observed in 2 participants. Applying the cutoff value of 5.3 kPa from a healthy population as 
described in the study by Han et al., significant fibrosis was detected in 56/101 patients. CAP 
values in this subgroup ranged from 165 dB/m to 385 dB/m, with a median of 239 dB/m (IQR 
74). Fifty-three (52.47%) participants had significant liver steatosis. The median BMI was 
24.74 (IQR 3.32). A BMI greater than 25 kg/m2 was found in 45 patients, and obesity was 
present in 5 patients. Age ranged from 24.35 to 71.33 years (median 42.36, IQR 13.4), and 
99/101 (98.01%) participants were male. The median CD4% was 29 (IQR 11, min-max 1-46), 
median CD8 was 44 (IQR 17, min-max 20-78) and CD4/8 ratio was 0.6383 (IQR 0.4502, min-
max 0.01282-1.76). The median known disease duration was 7 years (IQR, min-max 0.75-25). 
Eleven patients were diabetic, 21 had hypertension, and facial lipodystrophy was identified in 
12 individuals. The number of ART-experienced participants was 92 (91.09%). 
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Table 1. Study population characteristics. BMI: body mass index; CAP: controlled 
attenuation parameter; ART: antiretroviral therapy 
 
 
4.2 Univariate analysis of the association between the CAP value and different 
variables 
The examined continuous variables showed a strong association with the CAP value following 
the Pearson and Kendall-τ-rank correlation. According to the Bonferroni-correction, the 
associations of age (p<0.001), serum triglyceride (p<0.001), BMI (p<0.001) and disease 
duration (p<0.001) using the Pearson and Kendall-τ-rank correlation and liver stiffness with the 
Kendall-τ-rank correlation were considered significant (p<0.001). The association was only 
negative for the CD8 percentage. Among the categorical variables, the presence of hypertension 
was considered to be significant (p<0.001). 
Parameter Mean (Median) ± SD (IQR) [Min-Max] 
CD4 % 26.97 (27)  ± 8.93 (12) [1 - 48] 
CD8 % 45.59 (44.5)  ± 12.3 (17) [20 - 78] 
CD4/8 ratio 0.66 (0.63) ± 0.35 (0.39) [0.01 – 1.76] 
Age (years) 44.51 (42.36)  ± 11.06 (13.48) [24.35 - 78.13] 
BMI (kg/m2) 24.69 (24.16)  ± 3.18 (3.62) [18.04 – 37.83] 
Serum triglyceride (mmol/L) 2.543 (1.6)  ± 2.32 (2.3) [0 – 13.1] 
Serum cholesterol (mmol/L) 5.24 (5.2)  ± 1.5 (1.8) [0 – 10.9] 
Known HIV positivity (years) 9.13 (7)  ± 6.71 (9) [0.75 - 28] 
Liver Stiffness (kPa) 5.92 (5.2)  ± 3.96 (2) [3 – 36.3] 
CAP (dB/m) 245 (237)  ± 52.61 (67) [160 - 385] 
 N (%) 
ART ever taken 125 (91.9) 
Isolated anti-HBc positivity 13 (9.56) 
anti-HCV positivity 13 (9.56) 
HBsAg positivity 11 (8.08) 
Smoking 16 (11.75) 
Alcohol intake (>50g daily) 4 (2.94) 
Sex (male) 133 (97.8) 
Diabetes 13 (9.56) 
Hypertension 29 (21.32) 
Lipodystrophy 13 (9.56) 
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4.3 Multivariate regression models that predict the CAP value 
To identify significant covariates of the CAP value, a non-linear multivariate model was created 
using restricted cubic splines for the continuous variables. All examined parameters were 
entered into the model with the exception of smoking (33.09% of the values were missing) and 
gender (97.8% of the participants were male). The Wald-F test showed that joint non-linearity 
was not significant (p=0.1787); therefore, a linear model could be established. The regression 
showed a strong association with BMI (p<0.0001; regression coefficient 7.0696; 95% CI 4.268 
to 9.877). The associations with other covariates (disease duration, p=0.0433; regression 
coefficient 1.145; 95% CI -0.641 to 2.933; hypertension, p=0.0183; regression coefficient 
26.328; 95% CI 4.554 to 48.103) were also significant. Darunavir therapy as reported in the 
medical history was negatively associated with the CAP value (p=0.0193 regression coefficient 
-29.913; 95% CI -54.879 to -4.948). A significant negative association was also detected for 
liver stiffness (p=0.0183), but a 95% CI interval of the regression coefficient involved 0 (95% 
CI -3.189 to 1.775).  No significant collinearity was detected with the exception of the CD4/8 
ratio (virtual influence factor 10.85). Although penalization was not deemed to be necessary, a 
large number of variables compared with the study population was concerning. Therefore, 
model calibration and validation were performed, which revealed poor fitting of the model 
(adjusted R2 with optimism-corrected bootstrap 0.0813, shown). To address this problem, we 
penalized the model (adjusted R2 with optimism-corrected bootstrap 0.2698). As a result, BMI 
(p<0.0001; regression coefficient 3.94; 95% CI 1.969 to 5.910) and hypertension (p=0.0328; 
regression coefficient 16.557; 95% CI 1.396 to 31.71) remained significant. The estimated 
regression coefficients and confidence intervals are graphically presented in Figure 2.  
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Fig. 2. Multivariate analysis: covariates with regression coefficients and confidence 
intervals for the penalized model. The figure shows the regression coefficients of the 
covariates. For categorical variables, the change is understood as the change in the modal 
category, and for continuous variables, it is a change of 1 IQR. In each case, this is explicitly 
indicated by two values that are separated by a colon after the variable. BMI is expressed in 
kg/m2; age and length of known HIV positivity are expressed in years; and liver stiffness is 
expressed in kPa. ART, antiretroviral therapy; CAP, controlled attenuation parameter (dB/m); 
lipodystrophy, facial lipodystrophy. The thick dark blue lines represent 90% CIs, the thick light 
blue lines 95% CIs and the narrow light blue lines 99% CIs.   
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4.4 Univariate analysis of the association between liver stiffness and different 
variables 
A significant Kendall-τ-rank correlation was identified between the LS and CAP value 
(p<0.0001) and body mass index (p<0.0001). A non-significant but remarkable association was 
detected with age (p=0.007, adjusted p=0.203). With regard to categorical variables, no 
significant associations were identified, and the most pronounced correlation was the presence 
of arterial hypertension (p=0.045, adjusted p>1).  
4.5 Multivariate regression models predicting liver stiffness 
Non-linearity was deemed unnecessary (p=0.5658) in the multivariate model. The linear 
regression identified BMI (p=0.0236; regression coefficient 0.336; 95% CI 0.0465 to 0.6262), 
age (p=0.0458; regression coefficient 0.0959; 95% CI 0.0018 to 0.1899) and the history of 
taking lopinavir (p=0.0157; regression coefficient 2.458; 95% CI 0.478 to 4.438) as 
independent positive covariates. A history of taking zidovudine over the course of ART 
(p=0.0285; regression coefficient -2.015; 95% CI -3.813 to -0.217) and the presence of 
lipodystrophy (p=0.04; regression coefficient -3.693; 95% CI -6.453 to -0.933) were 
independent negative covariates. Nevertheless, the model exhibited a weak fit (R2=0.362, 
optimism-corrected R2=-0.1856). To improve goodness-of-fit and to address the problem of 
multidimensionality, we penalized the model. Although general model parameters improved 
(optimism-corrected R2=0.0525), the model still exhibited poor fitting, and no significant 
covariates were identified.  
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5 Discussion 
To the best of our knowledge, CAP had only been used in one other study performed in a large, 
unselected group of HIV-infected individuals to evaluate HS at the time of the publication our 
results. Using the same cutoff value (238 dB/m) and a methodology similar to our analysis, they 
detected HS in 40% of the participants. Our cross-sectional design resulted in similar findings, 
and we identified significant HS in 49% of the individuals living with HIV. However, Macías 
et al. used a dichotomized endpoint (the presence of significant HS). In contrast, we used a 
continuous scale of CAP values in the multivariate regressions for an HIV-infected population. 
One of the main advantages of CAP in comparison to other methods is that the quantitative 
measurement of HS can be integrated without losing information. Most recently, a longitudinal 
cohort was performed in a population of 326 HIV-infected individuals. After 12 months, the 
baseline 37% prevalence of significant HS (>238 dB/m) increased to 39%. Most studies 
assessing HS in HIV-infected patients enrolled a selected population with HCV co-infection. 
These studies, based on LB, reported a wide range of HS prevalence (11-72%).  
Few studies have assessed HS in HIV-mono-infected patients. The prevalence of HS was 31% 
and 52% in five studies using ultrasonography and 37% in another study using CT. Ingiliz et 
al. reported a 60% prevalence that was evaluated with LB in participants with persistent liver 
enzyme elevation. However, there are considerable concerns regarding the heterogeneity of the 
study population and the methods applied in these surveys. In another recently published cross-
sectional study in HIV-mono-infected individuals, NAFLD was identified in 48% of the 
participants using CAP measurements. 
 
Similar to hepatic steatosis, only a limited number of published studies have assessed liver 
stiffness in HIV-infected patients without HBV or HCV infection. In these publications the 
prevalence of liver fibrosis ranged from 11% to 42% using different cutoff values. The highest 
proportion was reported by Han et al., who identified abnormal LS values in 39/93 (42%) 
patients on ART for at least 12 months without hepatitis virus co-infection. Using the same 
cutoff value, the proportion of individuals with abnormal LS was even higher in our subgroup 
of HIV-mono-infected patients without significant alcohol consumption (56/101; 55.44%). In 
contrast, Merchante et al. identified 29/258 (11.2%) patients in their study population with 
significant liver fibrosis (cutoff >7.2 kPa). In the prospective study of Rivero-Juarez et al., the 
incidence of significant LF among HIV-infected individuals with liver damage of uncertain 
origin was reported to be 10.6% with the same cutoff. Applying their cutoff value (>7.2 kPa), 
we obtained similar results: abnormal LS values were detected using this cutoff in 10/101 
(9.9%) individuals in the subgroup. In a large study published by Mohr et al., a 10% prevalence 
of significant liver fibrosis was obtained with VTCE among 343 HIV-mono-infected patients 
(cutoff of 7.1 kPa) and 432 individuals living with HIV. Our results for the prevalence of 
significant liver fibrosis were very similar to those of published values. The observed outlier 
value in one participant in the HIV-mono-infected group refers to an advanced liver disease of 
unknown origin. Similarly, other observational studies in the HIV mono-infected population 
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also identified individuals with high grade fibrosis and even with cryptogenic cirrhosis. 
Recently, cirrhosis was identified in 5.2% percent of the HIV mono-infected patients (defined 
as LS>10.3 kPa) compared to the 0.6% of the uninfected control group.Nevertheless, these 
diverse results underline the importance of identifying better cutoff values for HIV-mono-
infected patients. The most reliable method to achieve this goal would be to perform a liver 
biopsy and compare the results with those of transient elastography. Nevertheless, to our 
knowledge, no such study has yet been conducted. Morse et al. verified the cutoff of 7.1 kPa in 
HIV-mono-infected patients with elevated transaminases undergoing liver biopsy, but as 
previously mentioned, adopting this cutoff for an unselected HIV-mono-infected population 
may underestimate the true prevalence. The discrepancies in cutoff values may lead to an 
unreliable estimation of the rate and grade of liver fibrosis. Therefore, instead of dichotomizing 
our study population to patients with abnormal and normal LS values, we used a continuous 
scale of LS for further correlation and regression analyses to avoid uncertainty arising from 
using a pre-defined “abnormal” value as the cutoff.  Regarding the general patient 
characteristics of the study population, demographic and anthropometric parameters, namely 
age and BMI, were similar to the findings of observational VTCE studies of large unselected 
patient groups, with the notable exception of the high proportion of male participants in our 
participant population. Correspondingly, because the HIV transmission route was almost 
exclusively sexual, the prevalence of HCV co-infection remained low, similar to the reported 
values among MSM PLWH of 1-12%. In contrast, among HIV-infected IVDUs, 72-95% were 
found to be co-infected with HCV. Therefore, our findings are likely explained by the absence 
of intravenous drug users in our study population.  
Regarding HBV, the HBsAg seroprevalence (8.08%) was both comparable to the reported 
values in HIV-infected IVDU (7-10%) and the MSM (9-17%) populations. Nevertheless, the 
identified proportion of patients with HBsAg was slightly higher than the ones identified in the 
largest observational VTCE studies of unselected HIV-infected patient groups (5-6.7%). If 
isolated anti-HBc positivity was also taken into account, then roughly one-fifth of the study 
population had contracted HBV. Nevertheless, the clinical significance of isolated anti-HBc 
positivity is not well-defined in PLWH. However, it does not have an impact on HIV 
progression of liver-related mortality, and individuals with isolated anti-HBc positivity have a 
significantly shorter survival than those with positive anti-HBs at baseline, suggesting a role of 
HIV-associated immunologic changes in the presence of this marker.  
Although alcohol consumption in Hungary is one of the highest in the world, with an APC 
(alcohol per capita consumption) of 13.3 L of pure alcohol annually, only a small proportion 
(2.94%) of the patients reported regular alcohol intake. A high index of suspicion should be 
maintained about the generalizability, especially in terms of data about addictive substance use, 
of the mode of HIV transmission and hepatitis co-infections, given the possible absence of non-
compliance in our study population. 
The prevalence of diabetes (9.56%) was somewhat higher than the prevalence in the general 
adult Hungarian population (7.5%), but it was comparable to the prevalence (7-13%) reported 
from PI, stavudine and zidovudine-experienced HIV patients. However, whether HIV infection 
itself increases the risk of diabetes remains unclear. Interestingly, our identified DM prevalence 
was higher than the reported values from similar studies (4.4-5%). Although assessing 
comparability is difficult given the different definitions of DM, our results may reflect an 
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unfavorable metabolic profile of the Hungarian HIV-infected population compared with the 
Spanish and German HIV-infected populations reported in the previous studies, which could 
be partially explained by the high proportion of zidovudine and PI-exposed individuals and the 
potential high cumulative exposure to these ARVs. The prevalence of hypertension portrays a 
similar profile. In our study, it was similar (21.32%) to the general Hungarian population 
(22.6%), but we should note that our results likely constitute an underestimation because 
hypertension was defined by the regular intake of an antihypertensive.  
In our study, using univariate analysis, ART medications were not significantly associated with 
steatosis. In the multivariate analysis, darunavir exposure was a significant independent 
variable with lower CAP values. Darunavir has previously been shown to have a more favorable 
metabolic profile (especially with regard to serum lipid level changes) than older PIs such as 
LPV/r. Our findings may provide additional support for these observations. It must be 
emphasized, however, that this association disappeared after penalizing the model. Thus, the 
generalizability of this result remains questionable. Regarding immune dysregulation, we used 
the CD4/8 ratio as a surrogate marker. Most other studies did not find an association between 
CD4 or CD8 cell counts, or the CD4/8 ratio, and HS. Our results were similar because after 
adjustment, none of these values were significant. Another possible marker of immune 
activation is the length of known HIV positivity, which may refer to a cumulative amount of 
viral replication and may refer to triggered immunologic alterations. With multivariate models 
the association with this value remained non-significant after penalization. Therefore, a 
reasonable link between CAP and ARVs, or markers of HIV-induced immune activation, 
cannot be confirmed.  
In contrast, metabolic factors showed a strong association with the CAP value. In the univariate 
analysis, BMI, age, hypertension and serum triglycerides were significantly associated with the 
CAP measurements. In the multivariate models, BMI remained significant with a narrow 95% 
CI of the regression coefficients not involving zero. These findings are in accord with the only 
other similarly published study from Spain performed by Macías et al., in which BMI was the 
only significant independent covariate, with an adjusted odds ratio of 1.34 (95% CI 1.22–1.47; 
p<0.001). Later, BMI was also indentified as the only independent predictor (B (standard error): 
9.03 (1.9); p< 0.001) of CAP value progression. Moreover, in the cross-sectional study of 
Vuille-Lessard et al., BMI also showed the greatest effect size on significant CAP value 
(adjusted odds ratio 4.86, 95% CI 2.55-9.26).  
 The results for hypertension were also convincing. This covariate was independently 
associated with CAP the multivariate models. Altogether, the association with this factor was 
not as impressive as with BMI, but it was still independently associated with CAP and should 
thus be considered as a main driving force of HS in individuals living with HIV. According to 
our findings, neither HCV nor HBV co-infection was associated with HS. Previous studies have 
reported similar results. 
In the subgroup analysis of HIV-mono-infected patients without clinically significant alcohol 
consumption, significant positive correlations were observed for CAP and BMI in the univariate 
analysis. However, in the multivariate models, no significant association could be identified if 
the models were penalized to avoid overfitting. Therefore, an independent association with liver 
stiffness remains to be determined. Previous studies investigating HIV-mono-infected patients 
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identified an association of metabolic factors, such as central obesity in HIV/HCV co-infection. 
A study using the non-invasive APRI score in 432 HIV-mono-infected patients enrolled in the 
Center for AIDS Research Database also identified diabetes and detectable HIV viremia as 
independent covariates for significant fibrosis after controlling for active alcohol use and site. 
These results shed light on the possible importance of metabolic conditions in the development 
of LF, which can be triggered by ongoing HIV replication. With regard to ART, no ARV was 
found to be significantly associated with LS. Han et al. found that the cumulative exposure to 
boosted PIs was a significant independent negative predictor. The authors concluded that 
ritonavir boosting may provide a protective effect. Considering the metabolic changes 
associated with boosted protease inhibitors, this result is surprising. Associations between 
didanosine and stavudine and liver fibrosis have been previously described. Clearly, further 
prospective, controlled trials will be needed to clarify the role of these side effects in the 
pathogenesis of LF in HIV-infected individuals. 
A published analysis performed on the same subgroup of HIV-mono-infected individuals used 
an alternative approach (Sulyok et al. 2017). Bayesian Model Averaging (BMA) provided a 
high support for age (Posterior Effect Probability-PEP: 84.5%), moderate for BMI (PEP: 
49.3%), CD4/8 ratio (PEP: 44.2%) and lipodystrophy (PEP: 44.0%). These findings overall 
suggest that age and BMI have a positive association with LS, while CD4/8 ratio and 
lipodystrophy are rather negatively associated.  
These results shed light on the possible importance of ageing, overweight and HIV-induced 
immune dysregulation in the development of liver fibrosis in the HIV-infected population. 
Nonetheless, these published findings by Sulyok et al. clearly underscore the advantages of 
using alternative modelling strategies and variable selection methods in small datasets. 
  
Our study has considerable limitations, the relatively small sample size of which is the most 
important. However, the proposed sample size was calculated based on a higher expected 
proportion of HS than observed. Given the numerous covariates, two different approaches were 
utilized to address overfitting, namely the penalization and post-hoc predictor selection, but the 
models still performed relatively poor, especially in the subgroup analysis. Another important 
limitation is the possibility of selection bias and significant confounders. The main strength of 
our study is the use of a non-invasive quantitative assessment of HS in an unselected group of 
individuals living with HIV. In addition to the novelty of this method, especially in this 
population, to our knowledge, this was the first study in the literature that did not use CAP 
cutoff values resulting in information loss. Furthermore, this observational study provided 
insight into epidemiologic data about the non-AIDS defining metabolic conditions and 
characteristics of the Hungarian HIV-infected population.  
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6 Conclusions 
In conclusion, the prevalence of significant HS in HIV-infected patients was high, affecting 
every second patient in the study population. According to the general patient population 
characteristics, diabetes was more prevalent, and other demographic, metabolic and 
immunologic parameters were comparable to those reported in similar studies. Notable 
exceptions were the low proportion of HCV-co-infected individuals, patients with significant 
daily alcohol intake and the absence of IVDUs. Significant independent covariates were 
metabolic factors (BMI, diabetes and hypertension, serum triglycerides). The association was 
unequivocally the most impressive with BMI. With the exception of an independent negative 
relation in the unpenalized model with darunavir exposure, cART and ARVs were not 
significantly associated with CAP values. Thus, our findings reflect the overwhelming 
importance of metabolic factors in HS. Lifestyle modification, dietary counseling and physical 
activity are paramount in fighting NAFLD and should be included in the care of HIV patients. 
To better identify the target group of individuals with ongoing liver steatosis and fibrosis, non-
invasive CAP and LS measurements with transient elastography could be considered as regular 
screening methods because TE is already recommended for the annual evaluation of 
HIV/hepatitis co-infected patients according to the EACS guideline. However, the role of other 
metabolic factors, such as HIV-induced chronic immune activation, in NAFLD should not be 
underestimated, and cART of all HIV-infected individuals, regardless of CD4 cell count, is the 
cornerstone of prevention of non-AIDS-defining morbidities. Furthermore, significant hepatic 
fibrosis (LS >7.1 kPa) was detectable in one out of every ten patients in the subgroup of HIV-
mono-infected individuals without significant daily alcohol intake. We were unable to show 
any meaningful statistical relationship between LS and any of the analyzed parameters, 
therefore, further investigations in larger patient populations will be performed in future 
analyses. As future directions, longitudinal data collection would be desirable. Further 
prospective studies and the organization of patient registries are warranted to better understand 
the epidemiology, burden and possible clinical consequences of NAFLD, as this common cause 
of liver disease in HIV-infected and uninfected individuals is fueled by the ongoing, silent 
epidemic of obesity. 
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